This combined therapy can prompt PDAC tumor cells to secrete various SASP factors, including angiogenic factors (VEGF), platelet-derived growth factor (PDGFA/B), fibroblast growth factor 2 (FGF2), and matrix metalloproteinases (MMP-2/3/7/9/10), which subsequently enhance endothelial cell proliferation, tubular structure formation, and vascular remodeling [147]. Here, FGF2 is linked to neoplasm.